Clinical Trial: A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects with Stable Parkinson''s Disease

A Multicenter, Open-Label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects with Stable Parkinson’s Disease

This study has been completed.

Sponsored by: Schwarz Pharma
Information provided by: Schwarz Pharma
ClinicalTrials.gov Identifier: NCT00139867

Purpose

The objective of this trial was to assess subject preference for PARCOPA, carbidopa/levodopa Orally Disintegrating Tablets (ODT), compared with conventional carbidopa/levodopa tablets, in subjects with stable Parkinson’s disease.
Condition Intervention Phase
Parkinson’s Disease
 Drug: PARCOPA
Phase III

MedlinePlus consumer health information 

Study Type: Interventional
Study Design: Randomized, Open Label, Dose Comparison, Crossover Assignment

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both
Criteria

Inclusion Criteria:

  • Stable Parkinson’s Disease

Exclusion Criteria:

  • Not using carbidopa/levodopa tablets

Location Information


Wisconsin
      Schwarz, Mequoin,  Wisconsin,  United States

Study chairs or principal investigators

Patricia Witt,  Study Director,  Schwarz Pharma   

More Information

Study ID Numbers:  SP780
Last Updated:  August 30, 2005
Record first received:  August 29, 2005
ClinicalTrials.gov Identifier:  NCT00139867
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-13

Resources




Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us